EU Chip Industry Faces Growing Risks From China Export Controls and U.S. Technology Dependence: Report 
Suncorp Cuts 2026 Premium Growth Forecast as Australia, New Zealand Markets Weaken 
Northern Star Appoints New CEO as Activist Elliott Pushes for Leadership Overhaul 
Trump Reports $1.4 Billion in Crypto Income as Digital Assets Become Top Wealth Source 
Anthropic Tightens AI Access Controls After Reports of China-Based Workarounds 
Kioxia Bets on AI Memory Boom With Next-Gen NAND Production in Japan 
SoftBank’s LY Corp, Bain Raise Kakaku.com Bid to ¥670 Billion, Intensifying Takeover Battle 
Super Micro Employees Detained in Taiwan AI Server Export Investigation 
Samsung to Invest $90 Billion in South Korea to Expand AI Chip, Display, and Battery Production 
TetherMax Rebranding Highlights Official Exchange Partnerships as Foundation of Trust 
Kuaishou Stock Jumps as Kling AI Secures $2 Billion Funding Round 
Apple Expands iPhone Lineup, Boosts Foldable iPhone Production Plans Through 2027 
SK Holdings, KKR Launch $1.3B Renewable Energy Venture in South Korea 
Trump Administration to Launch Voluntary AI Standards for Frontier Models 
OpenAI Proposes 5% U.S. Government Stake Amid AI Policy Talks 
When it comes to the red-hot sector of psychedelics, there’s no shortage of companies looking to enter the market. Quantity over quality can be an issue for any new industry, with hundreds of companies scrambling to stake their claim. However, it appears that a leader has emerged in the field. According to a recent survey by StrawPoll, Denver based Mydecine Innovations Group (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) ranks as the “favourite” publicly traded company in the psychedelic sector.
This comes as no surprise following Mydecine’s recent landmark progress in psychedelic research across the board. This year has been an important one for the company after successfully completing the first legal import of psychedelic mushrooms to Canada. This marks a major first step in the creation of a comprehensive psychedelic supply chain. In addition to Mydecine’s import capabilities, the company has announced an upcoming clinical trial to study the use of psychedelics in the treatment of PTSD. The first-of-its-kind clinical trial is a major step in the company’s goals to revolutionize the treatment of mental health and wellbeing. These trials are global in scope, with research taking place in 7 countries around the world.
Beyond clinical research and design, Mydecine is also innovating in the world of tech, with the creation of a remote mental health service delivery platform called “Mindleap''. It appears the company has effectively diversified and Mydecine’s CEO, Josh Bartch, attributes their recent success to this diverse set of capabilities.
“One thing about Mydecine that’s incredibly unique is that we’re fully vertically integrated, so as it pertains to psychedelic assisted psychotherapy, we really have an A-Z capability.”
Mydecine is quickly becoming the all-in-one brand in the space of psychedelics. With a recent uplisting to the NEO stock exchange, this novel industry leader has significant potential and will be one to watch moving forward.
This article does not necessarily reflect the opinions of the editors or the management of EconoTimes.
